Immunomodulation by statins: Inhibition of cholesterol vs. isoprenoid biosynthesis

Goldstein, 1990, Regulation of the mevalonate pathway, Nature, 343, 425, 10.1038/343425a0 Van Aelst, 1997, Rho GTPases and signaling networks, Genes Dev, 11, 2295, 10.1101/gad.11.18.2295 Mackay, 1998, Rho GTPases, J Biol Chem, 273, 20685, 10.1074/jbc.273.33.20685 Gotto, 1999, Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth council meeting, Circulation, 99, E1, 10.1161/01.CIR.99.8.e1 Maron, 2000, Current perspectives on statins, Circulation, 101, 207, 10.1161/01.CIR.101.2.207 Pedersen, 1999, Statin trials and goals of cholesterol-lowering therapy after AMI, Am Heart J, 138, S177, 10.1016/S0002-8703(99)70340-6 Hebert, 1997, Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials, JAMA, 278, 313, 10.1001/jama.278.4.313 Monks, 1998, Three-dimensional segregation of supramolecular activation clusters in T cells, Nature, 395, 82, 10.1038/25764 Grakoui, 1999, The immunological synapse: a molecular machine controlling T cell activation, Science, 285, 221, 10.1126/science.285.5425.221 Der Merwe, 2002, Immunology. The immunological synapse – a multitasking system, Science, 295, 1479, 10.1126/science.1069896 Kwak, 2000, Statins as a newly recognized type of immunomodulator, Nat Med, 6, 1399, 10.1038/82219 Kwak, 2001, The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells, Swiss Med Wkly, 131, 41 Sadeghi, 2001, Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors, Transplantation, 71, 1262, 10.1097/00007890-200105150-00014 Youssef, 2002, The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, Nature, 420, 78, 10.1038/nature01158 Neuhaus, 2002, Statins as immunomodulators: comparison with interferon-beta 1b in MS, Neurology, 59, 990, 10.1212/WNL.59.7.990 Lawman, 2004, Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice, J Immunol, 173, 7641, 10.4049/jimmunol.173.12.7641 Kuipers, 2005, Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains, Hum Immunol, 66, 653, 10.1016/j.humimm.2005.04.004 Kuipers, 2006, Simvastatin affects cell motility and actin cytoskeleton distribution of microglia, Glia, 53, 115, 10.1002/glia.20269 Yilmaz, 2004, HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis, Atherosclerosis, 172, 85, 10.1016/j.atherosclerosis.2003.10.002 Kuipers HF. CCR5 in multiple sclerosis: expression, regulation, and modulation by statins. Thesis; 2007. ISBN:978-90-9021648-5. Wagner, 2002, 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells, Arterioscler Thromb Vasc Biol, 22, 1784, 10.1161/01.ATV.0000037098.20829.31 Townsend, 2004, Lovastatin modulation of microglial activation via suppression of functional CD40 expression, J Neurosci Res, 78, 167, 10.1002/jnr.20234 Kawakami, 2002, Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions, Circ Res, 91, 263, 10.1161/01.RES.0000028454.42385.8B Rezaie-Majd, 2003, Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients, Arterioscler Thromb Vasc Biol, 23, 397, 10.1161/01.ATV.0000059384.34874.F0 Weber, 1997, HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia, J Am Coll Cardiol, 30, 1212, 10.1016/S0735-1097(97)00324-0 Chung, 2002, Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells, Exp Mol Med, 34, 451, 10.1038/emm.2002.63 Takeuchi, 2000, Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC, Biochem Biophys Res Commun, 269, 97, 10.1006/bbrc.2000.2238 Zapolska-Downar, 2004, Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells, Life Sci, 75, 1287, 10.1016/j.lfs.2004.03.005 Meroni, 2003, Modulation of adhesion molecule expression on endothelial cells: to be or not to be?, J Thromb Haemost, 1, 2280, 10.1046/j.1538-7836.2003.00487.x Teupser, 2001, HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells, Biochem Biophys Res Commun, 289, 838, 10.1006/bbrc.2001.6066 Hiraoka, 2004, MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway, Life Sci, 75, 1333, 10.1016/j.lfs.2004.02.028 Dong, 2000, Cell fate decision: T-helper 1 and 2 subsets in immune responses, Arthritis Res, 2, 179, 10.1186/ar85 Rosenson, 1999, Inhibition of proinflammatory cytokine production by pravastatin, Lancet, 353, 983, 10.1016/S0140-6736(98)05917-0 Grip, 2000, Pravastatin down-regulates inflammatory mediators in human monocytes in vitro, Eur J Pharmacol, 410, 83, 10.1016/S0014-2999(00)00870-0 Leung, 2003, A novel anti-inflammatory role for simvastatin in inflammatory arthritis, J Immunol, 170, 1524, 10.4049/jimmunol.170.3.1524 Hillyard, 2004, Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes, Atherosclerosis, 172, 219, 10.1016/j.atherosclerosis.2003.11.004 Pahan, 1997, Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages, J Clin Invest, 100, 2671, 10.1172/JCI119812 Rezaie-Majd, 2002, Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients, Arterioscler Thromb Vasc Biol, 22, 1194, 10.1161/01.ATV.0000022694.16328.CC Ascer, 2004, Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients, Atherosclerosis, 177, 161, 10.1016/j.atherosclerosis.2004.07.003 Bellosta, 1998, HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler Thromb Vasc Biol, 18, 1671, 10.1161/01.ATV.18.11.1671 Kalela, 2001, Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases, Am J Cardiol, 88, 173, 10.1016/S0002-9149(01)01616-2 Romano, 2000, Inhibition of monocyte chemotactic protein-1 synthesis by statins, Lab Invest, 80, 1095, 10.1038/labinvest.3780115 Waehre, 2003, Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease, J Am Coll Cardiol, 41, 1460, 10.1016/S0735-1097(03)00263-8 Aktas, 2003, Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin, J Exp Med, 197, 725, 10.1084/jem.20021425 Hillyard, 2002, Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin, Clin Exp Pharmacol Physiol, 29, 673, 10.1046/j.1440-1681.2002.03711.x Hillyard, 2004, Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease, Atherosclerosis, 175, 305, 10.1016/j.atherosclerosis.2004.03.018 Stanislaus, 2002, Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by lovastatin, Neurosci Lett, 333, 167, 10.1016/S0304-3940(02)00943-6 McKay, 2004, A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma, J Immunol, 172, 2903, 10.4049/jimmunol.172.5.2903 Kobashigawa, 1995, Effect of pravastatin on outcomes after cardiac transplantation, N Engl J Med, 333, 621, 10.1056/NEJM199509073331003 Hillyard, 2007, Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation, Atherosclerosis, 191, 319, 10.1016/j.atherosclerosis.2006.05.037 Hakamada-Taguchi, 2003, Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development, Circ Res, 93, 948, 10.1161/01.RES.0000101298.76864.14 Porreca, 2002, Increased transforming growth factor-beta (1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin, J Am Coll Cardiol, 39, 1752, 10.1016/S0735-1097(02)01857-0 Gegg, 2005, Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction, J Immunol, 174, 2327, 10.4049/jimmunol.174.4.2327 Greenwood, 2003, Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis, FASEB J, 17, 905, 10.1096/fj.02-1014fje van den Elsen, 1998, Regulation of MHC class I and II gene transcription: differences and similarities, Immunogenetics, 48, 208, 10.1007/s002510050425 Boss, 2003, Transcriptional regulation of the MHC class II antigen presentation pathway, Curr Opin Immunol, 15, 105, 10.1016/S0952-7915(02)00015-8 van den Elsen, 2004, Transcriptional regulation of antigen presentation, Curr Opin Immunol, 16, 67, 10.1016/j.coi.2003.11.015 Muhlethaler-Mottet, 1997, Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA, EMBO J, 16, 2851, 10.1093/emboj/16.10.2851 van der Stoep, 2002, J Immunol, 169, 5061, 10.4049/jimmunol.169.9.5061 Holling, 2002, Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III, J Immunol, 168, 763, 10.4049/jimmunol.168.2.763 Wong, 2002, Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line, J Immunol, 169, 3112, 10.4049/jimmunol.169.6.3112 Ghosh, 1999, A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes, J Biol Chem, 274, 32342, 10.1074/jbc.274.45.32342 Kuipers, 2005, Statins and control of MHC2TA gene transcription, Nat Med, 11, 365, 10.1038/nm0405-365 Darnell, 1997, STATs and gene regulation, Science, 277, 1630, 10.1126/science.277.5332.1630 Madonna, 2005, Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts, J Biol Chem, 280, 13503, 10.1074/jbc.M411859200 Ortego, 1999, Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells, Atherosclerosis, 147, 253, 10.1016/S0021-9150(99)00193-8 Simons, 1997, Functional rafts in cell membranes, Nature, 387, 569, 10.1038/42408 Brown, 1998, Functions of lipid rafts in biological membranes, Annu Rev Cell Dev Biol, 14, 111, 10.1146/annurev.cellbio.14.1.111 Pralle, 2000, Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells, J Cell Biol, 148, 997, 10.1083/jcb.148.5.997 Xavier, 1998, Membrane compartmentation is required for efficient T cell activation, Immunity, 8, 723, 10.1016/S1074-7613(00)80577-4 Drake, 2001, Cutting edge: lipid raft integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8+ T cells, J Immunol, 166, 7009, 10.4049/jimmunol.166.12.7009 Cheng, 1999, A role for lipid rafts in B cell antigen receptor signaling and antigen targeting, J Exp Med, 190, 1549, 10.1084/jem.190.11.1549 Goebel, 2002, Lipid rafts, major histocompatibility complex molecules, and immune regulation, Hum Immunol, 63, 813, 10.1016/S0198-8859(02)00458-5 Anderson, 2000, Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation, Nat Immun, 1, 156, 10.1038/77842 Simons, 2000, Lipid rafts and signal transduction, Nat Rev Mol Cell Biol, 1, 31, 10.1038/35036052 Maltese, 1990, Posttranslational modification of proteins by isoprenoids in mammalian cells, FASEB J, 4, 3319, 10.1096/fasebj.4.15.2123808 Zhang, 1996, Protein prenylation: molecular mechanisms and functional consequences, Annu Rev Biochem, 65, 241, 10.1146/annurev.bi.65.070196.001325 Greenwood, 2006, Statin therapy and autoimmune disease: from protein prenylation to immunomodulation, Nat Rev Immunol, 6, 358, 10.1038/nri1839 Kato, 2004, Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells, Biochim Biophys Acta, 1689, 267, 10.1016/j.bbadis.2004.04.006 Cicha, 2004, Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo, Arterioscler Thromb Vasc Biol, 24, 2046, 10.1161/01.ATV.0000145943.19099.a3 Takemoto, 2001, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, Arterioscler Thromb Vasc Biol, 21, 1712, 10.1161/hq1101.098486 Meske, 2003, Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease, Eur J Neurosci, 17, 93, 10.1046/j.1460-9568.2003.02433.x Dunn, 2006, Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin, J Exp Med, 203, 401, 10.1084/jem.20051129 Stanislaus, 2001, Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis, J Neurosci Res, 66, 155, 10.1002/jnr.1207 Floris, 2004, Blood–brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study, Brain, 127, 616, 10.1093/brain/awh068 Sriram, 1997, Indictment of the microglia as the villain in multiple sclerosis, Neurology, 48, 464, 10.1212/WNL.48.2.464 Benveniste, 1997, Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis, J Mol Med, 75, 165, 10.1007/s001090050101 Nelson, 2002, Microglia in diseases of the central nervous system, Ann Med, 34, 491, 10.1080/078538902321117698 Jack, 2005, Microglia and multiple sclerosis, J Neurosci Res, 81, 363, 10.1002/jnr.20482 Trapp, 1999, Pathogenesis of tissue injury in MS lesions, J Neuroimmunol, 98, 49, 10.1016/S0165-5728(99)00081-8 Boven, 2006, Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis, Brain, 129, 517, 10.1093/brain/awh707 Vollmer, 2004, Oral simvastatin treatment in relapsing-remitting multiple sclerosis, Lancet, 363, 1607, 10.1016/S0140-6736(04)16205-3 Polman, 2004, Statins for the treatment of multiple sclerosis: cautious hope, Lancet, 363, 1570, 10.1016/S0140-6736(04)16237-5 Sena, 2003, Therapeutic potential of lovastatin in multiple sclerosis, J Neurol, 250, 754, 10.1007/s00415-003-1070-8 Sena, 2004, Statins for multiple sclerosis, Lancet, 364, 412, 10.1016/S0140-6736(04)16752-4